Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

Abstract Aim of the study was to evaluate possible associations between cognitive dysfunctions and development of Levodopa Induced Dyskinesia (LID). PD patients from the Parkinson’s disease Cognitive impairment Study cohort who underwent a baseline and follow-up neuropsychological evaluations were e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antonina Luca, Roberto Monastero, Roberta Baschi, Calogero Edoardo Cicero, Giovanni Mostile, Marco Davì, Vincenzo Restivo, Mario Zappia, Alessandra Nicoletti
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d731beaaf3cf4f1193423357eed5cbfd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d731beaaf3cf4f1193423357eed5cbfd
record_format	dspace
spelling	oai:doaj.org-article:d731beaaf3cf4f1193423357eed5cbfd2021-12-02T14:12:08ZCognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort10.1038/s41598-020-79110-72045-2322https://doaj.org/article/d731beaaf3cf4f1193423357eed5cbfd2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-79110-7https://doaj.org/toc/2045-2322Abstract Aim of the study was to evaluate possible associations between cognitive dysfunctions and development of Levodopa Induced Dyskinesia (LID). PD patients from the Parkinson’s disease Cognitive impairment Study cohort who underwent a baseline and follow-up neuropsychological evaluations were enrolled. Mild Cognitive Impairment (PD-MCI) was diagnosed according to MDS level II criteria. The following cognitive domains were evaluated: episodic memory, attention, executive function, visuo-spatial function and language. A domain was considered as impaired when the subject scored 2 standard deviation below normality cut-off values in at least one test for each domain. Levodopa equivalent dose, UPDRS-ME and LID were recorded at baseline and follow-up. To identify possible neuropsychological predictors associated with the probability of LID development at follow-up, Cox proportional-hazards regression model was used. Out of 139 PD patients enrolled (87 men, mean age 65.7 ± 9.4), 18 (12.9%) were dyskinetic at baseline. Out of 121 patients non-dyskinetic at baseline, 22 (18.1%) developed LID at follow-up. The impairment of the attention and executive domains strongly predicted the development of LID (HR 4.45;95%CI 1.49–13.23 and HR 3.46; 95%CI 1.26–9.48 respectively). Impairment of the attention and executive domains increased the risk of dyskinesia reflecting the alteration of common cortical network.Antonina LucaRoberto MonasteroRoberta BaschiCalogero Edoardo CiceroGiovanni MostileMarco DavìVincenzo RestivoMario ZappiaAlessandra NicolettiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Antonina Luca Roberto Monastero Roberta Baschi Calogero Edoardo Cicero Giovanni Mostile Marco Davì Vincenzo Restivo Mario Zappia Alessandra Nicoletti Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
description	Abstract Aim of the study was to evaluate possible associations between cognitive dysfunctions and development of Levodopa Induced Dyskinesia (LID). PD patients from the Parkinson’s disease Cognitive impairment Study cohort who underwent a baseline and follow-up neuropsychological evaluations were enrolled. Mild Cognitive Impairment (PD-MCI) was diagnosed according to MDS level II criteria. The following cognitive domains were evaluated: episodic memory, attention, executive function, visuo-spatial function and language. A domain was considered as impaired when the subject scored 2 standard deviation below normality cut-off values in at least one test for each domain. Levodopa equivalent dose, UPDRS-ME and LID were recorded at baseline and follow-up. To identify possible neuropsychological predictors associated with the probability of LID development at follow-up, Cox proportional-hazards regression model was used. Out of 139 PD patients enrolled (87 men, mean age 65.7 ± 9.4), 18 (12.9%) were dyskinetic at baseline. Out of 121 patients non-dyskinetic at baseline, 22 (18.1%) developed LID at follow-up. The impairment of the attention and executive domains strongly predicted the development of LID (HR 4.45;95%CI 1.49–13.23 and HR 3.46; 95%CI 1.26–9.48 respectively). Impairment of the attention and executive domains increased the risk of dyskinesia reflecting the alteration of common cortical network.
format	article
author	Antonina Luca Roberto Monastero Roberta Baschi Calogero Edoardo Cicero Giovanni Mostile Marco Davì Vincenzo Restivo Mario Zappia Alessandra Nicoletti
author_facet	Antonina Luca Roberto Monastero Roberta Baschi Calogero Edoardo Cicero Giovanni Mostile Marco Davì Vincenzo Restivo Mario Zappia Alessandra Nicoletti
author_sort	Antonina Luca
title	Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
title_short	Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
title_full	Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
title_fullStr	Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
title_full_unstemmed	Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
title_sort	cognitive impairment and levodopa induced dyskinesia in parkinson’s disease: a longitudinal study from the pacos cohort
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/d731beaaf3cf4f1193423357eed5cbfd
work_keys_str_mv	AT antoninaluca cognitiveimpairmentandlevodopainduceddyskinesiainparkinsonsdiseasealongitudinalstudyfromthepacoscohort AT robertomonastero cognitiveimpairmentandlevodopainduceddyskinesiainparkinsonsdiseasealongitudinalstudyfromthepacoscohort AT robertabaschi cognitiveimpairmentandlevodopainduceddyskinesiainparkinsonsdiseasealongitudinalstudyfromthepacoscohort AT calogeroedoardocicero cognitiveimpairmentandlevodopainduceddyskinesiainparkinsonsdiseasealongitudinalstudyfromthepacoscohort AT giovannimostile cognitiveimpairmentandlevodopainduceddyskinesiainparkinsonsdiseasealongitudinalstudyfromthepacoscohort AT marcodavi cognitiveimpairmentandlevodopainduceddyskinesiainparkinsonsdiseasealongitudinalstudyfromthepacoscohort AT vincenzorestivo cognitiveimpairmentandlevodopainduceddyskinesiainparkinsonsdiseasealongitudinalstudyfromthepacoscohort AT mariozappia cognitiveimpairmentandlevodopainduceddyskinesiainparkinsonsdiseasealongitudinalstudyfromthepacoscohort AT alessandranicoletti cognitiveimpairmentandlevodopainduceddyskinesiainparkinsonsdiseasealongitudinalstudyfromthepacoscohort
_version_	1718391814736576512

Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

Ejemplares similares